Novel Mechanism of SR Calcium Regulation in Cardiac Dysfunction

SR 钙调节心脏功能障碍的新机制

基本信息

  • 批准号:
    8784234
  • 负责人:
  • 金额:
    $ 37.92万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2011
  • 资助国家:
    美国
  • 起止时间:
    2011-04-01 至 2015-12-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Heart failure is one of the most important diseases in the US and the world. Loss of contractility and blunted response to adrenergic stimulation are common pathophysiological features of a failing heart. Cardiac SR calcium cycling is a highly regulated process and its abnormalities play a major role in heart failure. Recently, our laboratory has identified a novel isoform of protein phosphatase 2C (PP2Ce) which has the following interesting features. PP2Ce is highly expressed in heart and the protein is targeted specifically on SR membrane of cardiomyocytes. PP2Ce has specific activity towards p-PLN without significant impact on p-RyR2. PP2Ce protein has a rapid turn- over rate and its expression is significantly induced by prolonged 2AR stimulation at post-transcriptional level. PP2Ce expression suppresses 2AR mediated induction in calcium transients and contractility, and promotes failure following ischemia/reperfusion injury. PP2Ce inactivation sustains 2AR induced contractility, protects against I/R injury and attenuates pressure-overload induced hypertrophy and heart failure. These findings lead to our exciting new hypothesis that PP2Ce is a novel phosphatase of PLN with a significant contribution to 2AR signaling and functional regulation in stressed hearts. In this proposal, we aim to uncover the regulatory mechanisms of PP2Ce expression and the functional significance of PP2Ce mediated signaling. Specifically, we plan to accomplish the following three aims: Specific aim 1: To investigate the molecular basis and cellular impact of PP2Ce-mediated PLN dephosphorylation. We will determine the interaction between PP2Ce and PLN, and the impact of PP2Ce expression/inactivation on SR calcium homeostasis. Specific aim 2: To investigate the regulatory mechanism of PP2Ce expression. We will dissect the contributing factors in PP2Ce protein expression, PLN targeting and 2AR mediated regulation of its turn-over. Specific aim 3: To determine the functional role of PP2Ce activity in intact heart. We will determine the functional impact of PP2Ce expression and inactivation in response to I/R injury and pressure-overload. In addition, we will determine functional significance of PLN in PP2Ce mediated cardiac protection and pathological remodeling.
描述(由申请人提供):心力衰竭是美国和世界上最重要的疾病之一。收缩力丧失和对肾上腺素能刺激的反应迟钝是衰竭心脏的常见病理生理特征。心脏SR钙循环是一个高度调节的过程,其异常在心力衰竭中起重要作用。最近,我们的实验室已经确定了一种新的蛋白磷酸酶2C(PP 2Ce)的亚型,它具有以下有趣的功能。PP 2Ce在心脏中高度表达,并且该蛋白特异性靶向于心肌细胞的SR膜。PP 2Ce对p-PLN具有特异性活性,对p-RyR 2没有显著影响。PP 2Ce蛋白具有快速的翻转速率,并且其表达在转录后水平被延长的2AR刺激显著诱导。PP 2Ce表达抑制2AR介导的钙瞬变和收缩性诱导,并促进缺血/再灌注损伤后的失败。PP 2Ce失活维持2AR诱导的收缩性,保护免受I/R损伤并减轻压力超负荷诱导的肥大和心力衰竭。这些发现导致了我们令人兴奋的新假设,即PP 2Ce是PLN的一种新型磷酸酶,对应激心脏中的2AR信号传导和功能调节有重要贡献。本研究旨在揭示PP 2Ce表达的调控机制及其介导的信号转导的功能意义。具体而言,我们计划实现以下三个目标:具体目标1:研究PP 2Ce介导的PLN去磷酸化的分子基础和细胞影响。我们将确定PP 2Ce和PLN之间的相互作用,以及PP 2Ce表达/失活对SR钙稳态的影响。具体目的2:研究PP 2Ce表达的调控机制。我们将剖析PP 2Ce蛋白表达,PLN靶向和2AR介导的调节其周转的贡献因素。具体目标3:确定PP 2Ce活性在完整心脏中的功能作用。我们将确定PP 2Ce表达和失活对I/R损伤和压力超负荷的功能影响。此外,我们将确定PLN在PP 2Ce介导的心脏保护和病理重塑中的功能意义。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Yibin Wang其他文献

Yibin Wang的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Yibin Wang', 18)}}的其他基金

Novel Regulatory Circuit in Cardiac Hypertrophy Via RNA Splicing
通过 RNA 剪接实现心脏肥大的新型调节电路
  • 批准号:
    8672729
  • 财政年份:
    2014
  • 资助金额:
    $ 37.92万
  • 项目类别:
Novel Regulatory Circuit in Cardiac Hypertrophy Via RNA Splicing
通过 RNA 剪接实现心脏肥大的新型调节电路
  • 批准号:
    8828777
  • 财政年份:
    2014
  • 资助金额:
    $ 37.92万
  • 项目类别:
Novel Function and Regulatory Mechanisms of Stress Kinase p38 in Heart
心脏应激激酶p38的新功能和调节机制
  • 批准号:
    8442307
  • 财政年份:
    2010
  • 资助金额:
    $ 37.92万
  • 项目类别:
Novel Function and Regulatory Mechanisms of Stress Kinase p38 in Heart
心脏应激激酶p38的新功能和调节机制
  • 批准号:
    8644859
  • 财政年份:
    2010
  • 资助金额:
    $ 37.92万
  • 项目类别:
Novel Function and Regulatory Mechanisms of Stress Kinase p38 in Heart
心脏应激激酶p38的新功能和调节机制
  • 批准号:
    8235829
  • 财政年份:
    2010
  • 资助金额:
    $ 37.92万
  • 项目类别:
Novel Function and Regulatory Mechanisms of Stress Kinase p38 in Heart
心脏应激激酶p38的新功能和调节机制
  • 批准号:
    7921260
  • 财政年份:
    2010
  • 资助金额:
    $ 37.92万
  • 项目类别:
Novel Function and Regulatory Mechanisms of Stress Kinase p38 in Heart
心脏应激激酶p38的新功能和调节机制
  • 批准号:
    8055537
  • 财政年份:
    2010
  • 资助金额:
    $ 37.92万
  • 项目类别:
ROLE OF P38 MAPK AND PP2C IN ISCHEMIC INJURY AND PROTECTION
P38 MAPK 和 PP2C 在缺血性损伤和保护中的作用
  • 批准号:
    6985005
  • 财政年份:
    2004
  • 资助金额:
    $ 37.92万
  • 项目类别:
Novel mechanisms in ER regulation in heart
心脏 ER 调节的新机制
  • 批准号:
    8090316
  • 财政年份:
    2003
  • 资助金额:
    $ 37.92万
  • 项目类别:
JNK Regulation of Cx43 Expression and Cardiac Remodeling
JNK 对 Cx43 表达和心脏重构的调节
  • 批准号:
    6737487
  • 财政年份:
    2003
  • 资助金额:
    $ 37.92万
  • 项目类别:

相似海外基金

A platform for rapidly generating live attenuated enterovirus vaccines
快速生成减毒肠道病毒活疫苗的平台
  • 批准号:
    24K02286
  • 财政年份:
    2024
  • 资助金额:
    $ 37.92万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
I-Corps: Translation potential of an efficient method to generate live-attenuated and replication-defective DNA viruses for vaccine development
I-Corps:一种有效方法的转化潜力,可生成用于疫苗开发的减毒活病毒和复制缺陷型 DNA 病毒
  • 批准号:
    2420924
  • 财政年份:
    2024
  • 资助金额:
    $ 37.92万
  • 项目类别:
    Standard Grant
Developing a robust native extracellular matrix to improve islet function with attenuated immunogenicity for transplantation
开发强大的天然细胞外基质,以改善胰岛功能,并减弱移植的免疫原性
  • 批准号:
    10596047
  • 财政年份:
    2023
  • 资助金额:
    $ 37.92万
  • 项目类别:
Live attenuated non-transmissible (LANT) Klebsiella pneumoniae vaccines
肺炎克雷伯氏菌减毒非传染性 (LANT) 活疫苗
  • 批准号:
    10742028
  • 财政年份:
    2023
  • 资助金额:
    $ 37.92万
  • 项目类别:
Protecting Pigs From Enzootic Pneumonia: Rational Design Of Safe Attenuated Vaccines.
保护猪免受地方性肺炎:安全减毒疫苗的合理设计。
  • 批准号:
    BB/X017540/1
  • 财政年份:
    2023
  • 资助金额:
    $ 37.92万
  • 项目类别:
    Research Grant
A “Goldilocks” live attenuated poultry vaccine for Infectious Coryza
用于传染性鼻炎的“Goldilocks”家禽减毒活疫苗
  • 批准号:
    LP210301365
  • 财政年份:
    2023
  • 资助金额:
    $ 37.92万
  • 项目类别:
    Linkage Projects
A novel live-attenuated Zika vaccine with a modified 5'UTR
一种带有改良 5UTR 的新型寨卡减毒活疫苗
  • 批准号:
    10730832
  • 财政年份:
    2023
  • 资助金额:
    $ 37.92万
  • 项目类别:
Combating melanoma with an attenuated bacterial therapeutic
用减毒细菌疗法对抗黑色素瘤
  • 批准号:
    10659841
  • 财政年份:
    2023
  • 资助金额:
    $ 37.92万
  • 项目类别:
Investigating Host and Viral Factors for Improved Design of Future Live Attenuated Vaccines for IBV
研究宿主和病毒因素以改进未来 IBV 减毒活疫苗的设计
  • 批准号:
    BB/V016067/1
  • 财政年份:
    2022
  • 资助金额:
    $ 37.92万
  • 项目类别:
    Research Grant
L2M NSERC-Bioengineering attenuated Sclerotinia sclerotiorum strains as bioherbicide for cereal production and lawn management
L2M NSERC-生物工程减毒核盘菌菌株作为谷物生产和草坪管理的生物除草剂
  • 批准号:
    576545-2022
  • 财政年份:
    2022
  • 资助金额:
    $ 37.92万
  • 项目类别:
    Idea to Innovation
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了